Table 2. Association of HLA-DP genotypes with chronicity and clearance of HBV infection.
| SNP ID | Genotype/geneticmodel | HBV carriers (%) n = 500 | Non-HBV infected subjects (%) n = 245 | HBV Clearance subjects (%) n = 259 | OR (95% CI)* | p* | OR (95% CI)† | p† |
| rs3077 | CC | 314 (62.8) | 123 (50.2) | 136 (52.5) | 1.00 | – | 1.00 | – |
| TC | 164 (33.0) | 103 (42.0) | 103 (39.8) | 0.68 (0.48–0.97) | 0.0312 | 1.31 (0.94–1.82) | 0.109 | |
| TT | 21 (4.2) | 19 (7.8) | 20 (7.7) | 0.41 (0.20–0.87) | 0.0193 | 2.35 (1.20–4.58) | 0.0125 | |
| Dominant | 0.64 (0.45–0.89) | 0.0089 | 1.42 (1.04–1.95) | 0.0284 | ||||
| Additive | 0.66 (0.50–0.87) | 0.0036 | 1.42 (1.10–1.83) | 0.0079 | ||||
| rs9277378 | GG | 283 (56.6) | 109 (44.5) | 115 (44.4) | 1.00 | – | 1.00 | – |
| AG | 192 (38.4) | 113 (46.1) | 112 (43.2) | 0.69 (0.49–0.98) | 0.0402 | 1.40 (1.00–1.94) | 0.0475 | |
| AA | 25 (5.0) | 23 (9.4) | 32 (12.4) | 0.43 (0.22–0.83) | 0.0119 | 3.20 (1.79–5.71) | 8.71×10−5 | |
| Dominant | 0.66 (0.47–0.93) | 0.0162 | 1.61 (1.18–2.2) | 0.0029 | ||||
| Additive | 0.68 (0.52–0.90) | 0.0058 | 1.62 (1.27–2.07) | 0.00011 | ||||
| rs3128917 | GG | 227 (45.4) | 83 (33.9) | 80 (30.9) | 1.00 | – | 1.00 | – |
| TG | 211 (42.2) | 122 (49.8) | 127 (49.0) | 0.68 (0.47–0.98) | 0.0395 | 1.64 (1.16–2.32) | 0.0056 | |
| TT | 62 (12.4) | 40 (16.3) | 52 (20.1) | 0.68 (0.41–1.14) | 0.141 | 2.22 (1.40–3.52) | 6.84×10−4 | |
| Dominant | 0.69 (0.49–0.98) | 0.0395 | 1.79 (1.29–2.48) | 0.00054 | ||||
| Additive | 0.79 (0.62–1.00) | 0.0561 | 1.52 (1.22–1.90) | 0.00024 |
All logistic regression analyses were adjusted for age and sex.
*
HBV carriers vs. non-HBV infected subjects.
†
HBV clearance subjects vs. HBV carriers.